PNAS published February 23, 2004. 101 (9) 2806-2810
A selection of technical resources.
Nature publication: AAV delivery of VHH Intrabodies
De Genst et al showcase the AAV delivery and intracellular in vivo expression of Isogenica’s LlamdA™ VHHs in monomeric and bivalent forms. Interestingly, these VHHs display preferences for distinct...
Isogenica’s PD-L1 VHH as Functional Antagonists
PD-1 is an immune checkpoint protein expressed on the surface of multiple types of immune cells, including antigen-stimulated T-cells and tumour specific T-cells1. Interaction between PD-1 and its...
Isogenica ISOXTEND® half-life extension for biotherapeutics
Our VHH-based ISOXTEND® technology protects biotherapeutics from kidney clearance by ‘piggybacking’ onto the serum albumin endocytic recycling pathway, significantly extending therapeutic...
CODON-PRECISE, SYNTHETIC, ANTIBODY FRAGMENT LIBRARIES BUILT USING AUTOMATED HEXAMER CODON ADDITIONS AND VALIDATED THROUGH NEXT GEN SEQUENCING Antibodies 2015, 4(2), 88-102
ANTI-LRP5/6 VHHS promote differentiation of WNT-hypersensitive intestinal stem cells Nature Communications 2019 10 (365)